Driving Innovation for the Treatment of Respiratory Diseases
We are advancing verekitug, the only known clinical-stage monoclonal antibody targeting the TSLP receptor, with the goal of transforming the daily lives of patients with chronic respiratory diseases.
By potently inhibiting the receptor for TSLP, the upstream driver of pro-inflammatory signaling, verekitug can disrupt the pathway implicated in many inflammatory diseases.
Our clinical trials are evaluating verekitug’s potential to treat respiratory diseases driven by chronic inflammation where TSLP signaling plays a key role, including severe asthma, CRSwNP and COPD.
Our experienced team works together every day to improve the lives of patients with respiratory diseases. We invest in and empower our employees so we can uplift patients.